Success Metrics

Clinical Success Rate
95.5%

Based on 42 completed trials

Completion Rate
95%(42/44)
Active Trials
17(23%)
Results Posted
43%(18 trials)
Terminated
2(3%)

Phase Distribution

Ph not_applicable
4
5%
Ph phase_1
3
4%
Ph phase_2
22
30%
Ph phase_3
40
54%
Ph phase_4
5
7%

Phase Distribution

3

Early Stage

22

Mid Stage

45

Late Stage

Phase Distribution74 total trials
Phase 1Safety & dosage
3(4.1%)
Phase 2Efficacy & side effects
22(29.7%)
Phase 3Large-scale testing
40(54.1%)
Phase 4Post-market surveillance
5(6.8%)
N/ANon-phased studies
4(5.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.3%

42 of 45 finished

Non-Completion Rate

6.7%

3 ended early

Currently Active

17

trials recruiting

Total Trials

74

all time

Status Distribution
Active(18)
Completed(42)
Terminated(3)
Other(11)

Detailed Status

Completed42
unknown11
Recruiting9
Active, not recruiting8
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
74
Active
17
Success Rate
95.5%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (4.1%)
Phase 222 (29.7%)
Phase 340 (54.1%)
Phase 45 (6.8%)
N/A4 (5.4%)

Trials by Status

unknown1115%
withdrawn11%
active_not_recruiting811%
completed4257%
not_yet_recruiting11%
recruiting912%
terminated23%

Recent Activity

Clinical Trials (74)

Showing 20 of 74 trialsScroll for more
NCT06124157Phase 2

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT04043494Phase 3

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Recruiting
NCT03959085Phase 3

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Recruiting
NCT03007147Phase 3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT02112916Phase 3

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Active Not Recruiting
NCT02101853Phase 3

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT03914625Phase 3

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

Active Not Recruiting
NCT02883049Phase 3

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Active Not Recruiting
NCT06533748Phase 2

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Recruiting
NCT06390319Phase 2

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Recruiting
NCT00558519Phase 2

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed
NCT03150693Phase 3

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Recruiting
NCT01190930Phase 3

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Active Not Recruiting
NCT02723994Phase 2

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Completed
NCT03571321Phase 1

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

Recruiting
NCT07072585Phase 2

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Not Yet Recruiting
NCT03117751Phase 2

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active Not Recruiting
NCT02521493Phase 3

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Active Not Recruiting
NCT00408005Phase 3

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Completed

Drug Details

Intervention Type
DRUG
Total Trials
74